Tazverik
Manufacturing · 1-10 Employees
View Company Info for Free
Overview
Website
www.tazverik.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Tazverik
Ipsen is a biopharmaceutical company that provides TAZVERIK® (tazemetostat), a prescription medicine specifically designed for adults with relapsed or refractory follicular lymphoma whose tumors exhibit an EZH2 mutation. This medication is aimed at patients who have undergone at least two prior systemic therapies and have no satisfactory alternative treatment options. TAZVERIK is noted for being the only FDA-approved oral monotherapy for this condition and is included in the NCCN Clinical Practice Guidelines for B-Cell Lymphomas. The company's services also include patient and healthcare professional resources to support treatment access and safety information.Explore more
Popular SearchesTazverikEpizyme IncSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tazverik your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Tazverik, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Tazverik has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Tazverik
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Tazverik launches new products
Click to see if Tazverik had a recent Job posting/layoffs
Earning: See what the market has to say on Tazverik recently announced quarterly report
Funding: Get notified immidiatlly once Tazverik has new funding data
Check out if Tazverik is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Tazverik
Compare insights from companies similar to Tazverik, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tazverik
<$5M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
Tazverik is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tazverik is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tazverik.
Tazverik Tech Stack
A closer look at the technologies used by Tazverik
Tazverik News & Media
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
— First and only EZH2 inhibitor approved by the NMPA —Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Epizyme, Inc. (“Epizyme”) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13), today announce a collaboration to research, develop, manufacture and commercialize TAZVERIK® in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the “Territory”). TAZVERIKEpizyme Reports Business Progress and Third Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported third quarter 2020 financial results. “2020 has been a year of big milestones for Epizyme, and we are executing our TAZVERIK® launches well, given the unprecedented challenges presented by the COVID-19 pandemic on FL patients’ access to their physicians and on ac
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tazverik
Sign Up For FreeTo access detailed company insights
Ipsen is a biopharmaceutical company that provides TAZVERIK® (tazemetostat), a prescription medicine specifically designed for adults with relapsed or refractory follicular lymphoma whose tumors exhibit an EZH2 mutation. This medication is aimed at patients who have undergone at least two prior systemic therapies and have no satisfactory alternativ... Read More
